KORU Medical Systems, Inc. (KRMD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 15% revenue increase and a 40% rise in net income, alongside improved gross margins. These indicators, coupled with positive cash flow, suggest robust financial health. Despite the absence of strategic updates, the financial metrics and optimistic forward-looking statements indicate potential for positive stock movement. The lack of negative sentiment in the Q&A further supports a positive outlook, likely resulting in a 2% to 8% stock price increase over the next two weeks.
Key Financial Performance
Revenue Revenue for Q1 2026 was $12.5 million, representing a 15% increase year-over-year. The growth was driven by strong demand for the company's infusion systems and expansion into new markets.
Gross Margin Gross margin improved to 65% in Q1 2026, up from 62% in Q1 2025. The improvement was attributed to operational efficiencies and cost-saving initiatives.
Net Income Net income for Q1 2026 was $2.1 million, compared to $1.5 million in Q1 2025, marking a 40% increase. This was due to higher revenue and improved cost management.
Operating Expenses Operating expenses increased to $6.8 million in Q1 2026, up from $6.2 million in Q1 2025, a 9.7% rise. The increase was primarily due to investments in R&D and sales initiatives.
Cash Flow from Operations Cash flow from operations was $3.2 million in Q1 2026, compared to $2.8 million in Q1 2025, a 14.3% increase. This was driven by improved profitability and better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that actual events or results could differ materially from their predictions and expectations due to risks and uncertainties. This implies potential risks in strategic execution and market conditions that could impact the company's performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Adams CFO
Bednar Piper
CEO Director
CFO Secretary
Caitlin Cronin
Canaccord Genuity
Conference Instructions
Cronin Canaccord
Director President
Division Chase
Division Frank
Division Jason
Division PM
EDT Greetings
Frank Takkinen
Genuity Corp
Group LLC
Inc Tharby
Jason Bednar
LLC Caitlin
LLC Research
Officer Tom
PM EDT
Piper Sandler
President Chief
Research Division
Sandler Co
Secretary Treasurer
Systems Conference
Takkinen Lake
Tharby CEO
Tom Adams
Treasurer Gilmartin
KRMD Transcript
KORU Medical Systems, Inc. (KRMD) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial performance with a 15% revenue increase and a 40% rise in net income, alongside improved gross margins. These indicators, coupled with positive cash flow, suggest robust financial health. Despite the absence of strategic updates, the financial metrics and optimistic forward-looking statements indicate potential for positive stock movement. The lack of negative sentiment in the Q&A further supports a positive outlook, likely resulting in a 2% to 8% stock price increase over the next two weeks.
KORU Medical Systems, Inc. (KRMD) Q4 2025 Earnings Call Transcript
Positive3-12
The earnings call reveals strong financial performance with a 23% YoY revenue growth and international expansion. The company raised its revenue guidance, maintained positive cash flow, and achieved positive adjusted EBITDA. Despite slight margin decreases, the strategic focus on expanding market share and new product launches is promising. The Q&A highlights further growth potential in international markets and new drug approvals. The overall sentiment is positive, with expectations of continued growth driven by strategic initiatives and market expansion, suggesting a likely positive stock price movement.
KORU Medical Systems, Inc. (KRMD) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call indicates strong international revenue growth and positive cash flow. Despite domestic revenue decline, the company has raised its revenue guidance and aims for 20%+ growth. The Q&A section highlights high nurse satisfaction and workflow improvements, existing reimbursement codes, and strong international expansion plans. Gross margin pressures are acknowledged but are being addressed. Overall, the optimistic guidance, international expansion, and raised revenue forecast outweigh domestic challenges, suggesting a positive stock price movement.
KORU Medical Systems, Inc. (KRMD) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call highlighted strong growth in prefilled syringes, a strategic focus on expanding international markets, and a positive cash flow reinvestment plan. Although there were some delays and uncertainties, the company is mitigating these effectively. The Q&A section revealed optimism about future growth, particularly with new product launches and international expansion. Overall, the sentiment is positive, with potential for stock price appreciation given the strong business fundamentals and strategic initiatives.
KRMD Slides
KRMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
